Positive Mid-Year Interim Clinical Progress Reported from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer June 10, 2026
Lancet Oncology publishes results of Pivotal Ph 3 Significant DFS Improvement with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer June 10, 2026
NEJM publishes results from ASCERTAIN-V Ph 1/2 trial of decitabine-cedazuridine + venetoclax in 1L AML patients ineligible for intensive induction chemo June 10, 2026
IBI343 (arcotatug tavatecan) Met Primary Endpoint in Ph 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA June 10, 2026
Ph 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes did not meet predefined threshold to support further development June 2, 2026
Primary Endpoints Met in Final Analysis of Ph 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC June 2, 2026
Ph 3 Trial of Sacituzumab Tirumotecan (sac-TMT) vs Chemo as 1L Treatment for Advanced TNBC Met Primary Endpoint of PFS May 26, 2026
Ph 2 ARASEC Data Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic CSPC May 21, 2026
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic HSPC May 21, 2026
Extended Clinical Benefit Over Multiple Clinical Endpoints Reported from Ph 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at longer Follow-up May 21, 2026
Updated Interim Results Announced From Ph 2 LEGEND trial of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC patients with CIS with or without concomitant papillary disease May 21, 2026
ZUSDURI Median DOR Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial May 21, 2026
Ph 3 VIKTORIA-2 Trial of Gedatolisib in 1L HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients May 21, 2026
Perioperative Imfinzi plus neoadjuvant EV showed statistically significant EFS/OS improvements in MIBC in Ph 3 VOLGA trial May 21, 2026
Positive Updated 12-Month Data Demonstrated Durable Responses in BCG-Naïve Cohort of Ph 2 ADVANCED-2 Trial of TARA-002 in NMIBC May 21, 2026
94.5% Six-Month Duration of Response reported from Ph 3 UTOPIA Trial of UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC May 21, 2026
Re-induction with ADSTILADRIN resulted in complete responses in 31% of initial non-responders with BCG-unresponsive NMIBC May 21, 2026
FAILED TRIAL: Ph 3 Trial of Fianlimab Combination in 1L Unresectable or Metastatic Melanoma did not reach statistical significance for PFS improvement May 21, 2026
TroFuse-005 Trial of Sacituzumab Tirumotecan (Sac-TMT) Met OS/PFS Primary Endpoints in Certain Patients With Advanced or Recurrent Endometrial Cancer May 21, 2026
